Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T06:00:52.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new phase II study design for a combination immunotherapy trial involving Ipilimumab and Nivolumab for advanced non-small cell lung cancer, with specific details on patient enrollment criteria and study collaborators.
    Difference
    48%
    Check dated 2025-04-16T15:03:46.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 9, 2025, while a date of March 25, 2025, has been removed.
    Difference
    0.4%
    Check dated 2025-04-09T10:37:30.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version (v2.14.3) and a new date for the results first posted, changing from January 9, 2025, to March 25, 2025.
    Difference
    0.3%
    Check dated 2025-04-01T23:44:15.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T21:29:49.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T13:54:36.000Z thumbnail image

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.